A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
NCT ID: NCT03809325
Last Updated: 2025-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
225 participants
OBSERVATIONAL
2018-11-21
2019-07-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Paliperidone Palmitate in Schizophrenia
NCT01860781
Study of Mental Care in Spain
NCT00824031
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
NCT00399334
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
NCT01959659
Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
NCT00528905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Schizophrenia
No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
Paliperidone Palmitate 3-Month Formulation (PP3M)
No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paliperidone Palmitate 3-Month Formulation (PP3M)
No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be currently receiving PP3M and have previously received 4 to 6 injections of PP3M
* Have the required language skills to participate in the online questionnaire, in the opinion of the physician
* Be able and willing to provide their informed consent for study participation
Exclusion Criteria
* Was switched to PP3M treatment within a clinical trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag International NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen-Cilag International NV Clinical Trial
Role: STUDY_DIRECTOR
Janssen-Cilag International NV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Brugmann
Brussels, , Belgium
Centre Médico Psychologique De Courbevoie
Asnières-sur-Seine, , France
Centre Medico Psychologique
Cagnes-sur-Mer, , France
Cabinet medical
Dax, , France
Centre Hospitalier Esquirol
Limoges, , France
CH de Jury
Metz, , France
CH Montauban
Montauban, , France
Hopital la Colombiere
Montpellier, , France
Centre Medico Psychologique Le Rembrandt
Nice, , France
Centre Hospitalier de Novillars
Novillars, , France
Centre Hospitalier Guillaume Regnier
Rennes, , France
Hopital Sainte Musse
Toulon, , France
Vivantes Klinikum Am Urban
Berlin, , Germany
NPZR - Neuropsychatrisches Zentrum Riem
München, , Germany
Kbo-Inn-Salzach-Klinikum GmbH
Wasserburg A. Inn, , Germany
Toldy Ferenc Kórház-Rendelőintézet
Cegléd, , Hungary
Kemenesaljai Egyesített Kórház-Szakorvosi Rendelointézet
Celldömölk, , Hungary
Sántha Kálmán Szakkórház
Nagykálló, , Hungary
Tolna Megyei Balassa Janos Korhaz
Szekszárd, , Hungary
Azienda Sanitaria Alto Adige
Bolzano, , Italy
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
Brescia, , Italy
CSM Frosinone
Frosinone, , Italy
Casa di Cura Villa Von Siebenthal
Genzano di Roma, , Italy
Centro Igiene Mentale ASL Salerno
Oliveto Citra, , Italy
SPDC Asltaranto
Statte, , Italy
Hosp. Abente E Lago
A Coruña, , Spain
Csm Miraflores
Alcobendas, , Spain
Csm Arganda Del Rey
Arganda, , Spain
Usmc Carmona
Carmona, , Spain
Hosp. Gral. Univ. Gregorio Maranon
Madrid, , Spain
Usmc Mairena Del Aljarafe
Mairena del Aljarafe, , Spain
Centre Hosp. de Manresa
Manresa, , Spain
Corporacio Sanitari Parc Tauli
Sabadell, , Spain
Hosp. Univ. de Torrevieja
Torrevieja, , Spain
Hosp. Clinico Univ. de Valencia
Valencia, , Spain
Csm Rondilla
Valladolid, , Spain
Hosp. Psiquiatrico Alava
Vitoria-Gasteiz, , Spain
Hosp. Univ. Miguel Servet
Zaragoza, , Spain
Birmingham & Solihull MH NHS FT
Birmingham, , United Kingdom
Leicester Partnership NHS Trust
Leicester, , United Kingdom
West London Mental Health Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R092670SCH4066
Identifier Type: OTHER
Identifier Source: secondary_id
CR108568
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.